<DOC>
	<DOC>NCT00951574</DOC>
	<brief_summary>In this phase III, multicenter study, 1200 patients with lung, breast, gastrointestinal (stomach, colon-rectum, pancreas), ovarian or head and neck cancer undergoing chemotherapy will be randomly assigned (at the beginning of cytotoxic therapy) in a 2:1 ratio and in double-blind conditions to a treatment with subcutaneous low molecular weight heparin (nadroparin calcium, one injection/day) or placebo for the overall duration of chemotherapy or up to a maximum of 4 months (+/- 10 days).</brief_summary>
	<brief_title>Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>INCLUSION CRITERIA: both sexes;aged&gt;18 years; suffering from different types of malignancies(lung, breast,gastric,colon rectum,pancreatic,ovarian,head and neck cancer)undergoing systemic chemotherapy, having signed Informed Consent prior to initiation of any study procedure. EXCLUSION CRITERIA: adjuvant and neoadjuvant chemotherapy; objectively confirmed venous or arterial thromboembolism in the last three months; antithrombotic treatment for other indications; life expectancy of less than 3 months; Performance Status&gt;2(ECOG); active bleeding or bleedings in the last four weeks requiring hospitalization,transfusion or surgical intervention; bleeding diathesis(prothrombin time&lt;70% or activated partial thromboplastin time ratio&gt;1.3),or platelet count&lt;50x10^9/L; cerebrovascular hemorrhage in the last six months; known active gastric or duodenal ulcer; known cerebral metastasis; cerebral aneurysm; IIIIV grade diabetic retinopathy; severe and uncontrolled hypertension(systolic blood pressure&gt;180 mmHg or diastolic blood pressure&gt;110 mmHg); chronic atrial fibrillation; acute endocarditis; acute pancreatitis; known hypersensitivity to unfractionated heparin or LMWH; previous occurrence of heparininduced thrombocytopenia; renal impairment (dependent on dialysis or creatinine higher than 2.5mg%); liver insufficiency (alanine aminotransferase,aspartate aminotransferase,alkaline phosphatase levels&gt;3 times the upper limit of the normal ranges and/or total bilirubin &gt;3.0 mg/ml); pregnancy or childbearing potential without adequate contraception; treatment with other investigational drugs or patient inclusion in other clinical trials; patients who are unable to fulfill the study requirements in terms of visits/compliance to treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>thromboembolism</keyword>
	<keyword>cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>low-molecular-weight-heparin</keyword>
	<keyword>nadroparin</keyword>
</DOC>